首页> 外文期刊>The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation >Influence of induction therapy, immunosuppressive regimen and anti-viral prophylaxis on development of lymphomas after heart transplantation: data from the Spanish Post-Heart Transplant Tumour Registry.
【24h】

Influence of induction therapy, immunosuppressive regimen and anti-viral prophylaxis on development of lymphomas after heart transplantation: data from the Spanish Post-Heart Transplant Tumour Registry.

机译:诱导疗法,免疫抑制方案和抗病毒预防措施对心脏移植后淋巴瘤发展的影响:西班牙心脏移植后肿瘤登记处的数据。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Lymphoma after heart transplantation (HT) has been associated with induction therapy and herpesvirus infection. It is not known whether anti-viral agents administered immediately after HT can reduce the incidence of lymphoma. METHODS: This study was a retrospective review of 3,393 patients who underwent HT in Spain between 1984 and December 2003. Variables examined included development of lymphoma and, as possible risk factors, recipient gender and age, induction therapies (anti-thymocyte globulin, OKT3 and anti-interleukin-2 receptor antibodies) and anti-viral prophylaxis (acyclovir or ganciclovir). To study the effect of evolving treatment strategy, three HT eras were considered: 1984 to 1995; 1996 to 2000; and 2001 to 2003. RESULTS: Induction therapy was employed in >60% of HTs, and anti-viral prophylaxis in >50%. There were 62 cases of lymphoma (3.1 per 1,000 person-years, 95% confidence interval: 2.4 to 4.0). Univariate analyses showed no influence of gender, age at transplant, HT era,pre-HT smoking or the immunosuppressive maintenance drugs used in the first 3 months post-HT. The induction agent anti-thymocyte globulin (ATG) was associated with increased risk of lymphoma, and prophylaxis with acyclovir with decreased risk of lymphoma. Multivariate analyses (controlling for age group, gender, pre-HT smoking and immunosuppression in the first 3 months with mycophenolate mofetil and/or tacrolimus) showed that induction increased the risk of lymphoma if anti-viral prophylaxis was not used (regardless of induction agent and anti-viral agent), but did not increase the risk if anti-viral prophylaxis was used. CONCLUSIONS: Induction therapies with ATG or OKT3 do or do not increase the risk of lymphoma depending on whether anti-viral prophylaxis with acyclovir or ganciclovir is or is not employed, respectively.
机译:背景:心脏移植术后的淋巴瘤(HT)与诱导疗法和疱疹病毒感染有关。 HT后立即给予抗病毒药物是否可以减少淋巴瘤的发病率尚不明确。方法:本研究是对1984年至2003年12月在西班牙进行的HT的3393例患者的回顾性回顾。所检查的变量包括淋巴瘤的发生以及可能的危险因素,受体性别和年龄,诱导疗法(抗胸腺细胞球蛋白,OKT3和抗白介素2受体抗体)和抗病毒药物(阿昔洛韦或更昔洛韦)。为了研究不断发展的治疗策略的效果,我们考虑了三个HT时代:1984年至1995年; 1990年至2005年。 1996年至2000年;结果:2001年至2003年。结果:HTs中> 60%的患者采用了诱导疗法,而> 50%的患者采用了抗病毒治疗。共有62例淋巴瘤病例(每千人年3.1例,95%置信区间:2.4至4.0)。单因素分析显示,性别,移植年龄,HT时代,HT前吸烟或HT后前3个月使用的免疫抑制维持药物均无影响。诱导剂抗胸腺细胞球蛋白(ATG)与淋巴瘤的风险增加有关,而阿昔洛韦的预防与淋巴瘤的风险减少有关。多变量分析(控制霉菌酸酯和/或他克莫司治疗的前三个月的年龄,性别,HT前吸烟和免疫抑制)表明,如果不使用抗病毒药物,则诱导会增加淋巴瘤的风险(与诱导剂无关)和抗病毒剂),但如果使用抗病毒预防措施,则不会增加风险。结论:取决于是否采用阿昔洛韦或更昔洛韦的抗病毒预防,分别用ATG或OKT3进行诱导治疗不会增加淋巴瘤的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号